Many people use GLP-1 medications long-term, as they not only support weight loss but also help maintain results
None are currently FDA-approved for T1D, but off-label prescribing has been rising sharply and the clinical data is starting to catch up
The commentary concluded that, based on current knowledge, patients should not stop taking semaglutide on this account alone, especially given potential increases in morbidity from conditions that are well controlled by semaglutide, potential adverse effects of hyperglycemia caused by abrupt cessation of treatment, and the seemingly low absolute risk of NAION
The same applies to semaglutide and all other GLP-1 formulations
Potential Benefits of GLP-1 Agonists Side Effects of GLP-1 Agonists Next Steps: Taking Action with GLP-1 Therapies Conclusion GLP-1, or Glucagon-like Peptide-1, is transforming the way we approach metabolic health